Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Sponsor
Hellenic Oncology Research Group
Study ID
NCT00749567
Phase
PHASE2
Status
Terminated

Conditions

  • Non-small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
  • Bevacizumab — DRUG
    Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity

Study Details

The purpose of this study is to evaluate the efficacy and toxicity of combination of erlotinib and bevacizumab in patients with locally advanced or metastatic, non-squamous non-small cell lung cancer, who progressed after first line treatment. Pretreatment with one of the two agents would not excluded patients from the study, in order to evaluate whether the combination of the two biologic agents could reverse tumor resistance.

Key Dates

First listed
Sep 9, 2008
Start date
Jul 31, 2008
Status verified
Sep 2015
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010

Study Design

Enrollment
13 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Erlotinib/Bevacizumab

Primary Outcome Measure

Overall response rate [ Time Frame: Objective responses confirmed by CT or MRI (on 3rd and ]

Related Studies